786706-01-2

Basic information

• Product Name: 7,8-bis-(1,1-dimethyl-allyloxy)-2-phenyl-4H-chromen-4-one
• Synonyms: 7,8-bis-(1,1-dimethyl-allyloxy)-2-phenyl-4H-chromen-4-one
• CAS NO: 786706-01-2
• Molecular Weight: 390.479
• Mol File: 786706-01-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 7,8-bis-(1,1-dimethyl-allyloxy)-2-phenyl-4H-chromen-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 7,8-bis-(1,1-dimethyl-allyloxy)-2-phenyl-4H-chromen-4-one(786706-01-2)
• EPA Substance Registry System: 7,8-bis-(1,1-dimethyl-allyloxy)-2-phenyl-4H-chromen-4-one(786706-01-2)

Safety Data

• Hazardous Substances Data: 786706-01-2(Hazardous Substances Data)

Upstream product

• 2652-27-9 1-(3,4-bis(benzyloxy)-2-hydroxyphenyl)ethanone 
• 38183-03-8 7,8-dihydroxyflavone 
• 93827-33-9 C₂₉H₂₄O₄ 
• 500866-00-2 C₂₉H₂₂O₄ 
• 528-21-2 2',3',4'-trihydroxyacetophenone 
• 786706-00-1 7,8-bis-(1,1-dimethyl-prop-2-ynyloxy)-2-phenyl-4H-chromen-4-one 

Downstream Products

• 1033873-86-7 C₂₅H₂₆O₄ 

Relevant articles and documents

Studies on gambogic acid (IV): Exploring structure-activity relationship with IκB kinase-beta (IKKβ)

Previously we have reported a series of gambogic acid's analogs and have identified a compound that possessed comparable in vitro growth inhibitory effect as gambogic acid. However, their target protein as well as the key pharmacophoric motifs on the target have not been identified yet. Herein we report that gambogic acid and its analogs inhibit the activity of IκB Kinase-beta (IKKβ) through suppressing the activation of TNFα/NF-κB pathway, which in turn induces A549 and U251 cell apoptosis. IKKβ can serve as one of gambogic acid's targets. The preparation of the compounds was carefully discussed in the article. Caged 4-oxa-tricyclo[4.3.1.03,7]dec-2-one xanthone, which was identified as the pharmacophoric scaffold, represents a promising therapeutic agent for cancer and useful probe against NF-κB pathway.

Methods of treating diseases responsive to induction of Apoptosis and screening assays

The present invention pertains to a method of treating, preventing or ameliorating a disease responsive to induction of the caspase cascade in an animal, comprising administering to the animal a compound which binds specifically to one or more Apoptosis Inducing Proteins (AIPs). AIPs include Transferrin Receptor Related Apoptosis Inducing Proteins (TRRAIPs), Clathrin Heavy Chain Related Apoptosis Inducing Proteins (CHCRAIPs), IQ motif containing GTPase Activating Protein Related Apoptosis Inducing Proteins (IQGAPRAIPs), and Heat Shock Protein Related Apoptosis Inducing Proteins (HSPRAIPs). The present invention also relates to screening methods useful for drug discovery of apoptosis inducing compounds. In particular, the screening methodology relates to using AIPs as a target for the discovery of apoptosis activators useful as anticancer agents. The screening methods of the present invention can employ homogenous or heterogenous binding assays using purified or partially purified AIPs; or whole cell assays using cells with altered levels of one or more AIPs. The invention also contemplates use of gambogic acid or GA-related compounds which bind AIPs and can accordingly be used to raise antibodies useful for drug discovery. Alternatively, labeled GA is used for competitive binding assays for drug discovery. Such assays afford high throughput screening of chemical libraries for apoptosis activators.